Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.
Level 2 - randomized trial
Secondary analysis of a randomized controlled dose-response trial.
PubMed 18160461 · doi:10.1210/jc.2007-1692
What was done
Researchers conducted a secondary analysis of a 20-week dose-response study in 60 older men (aged 60–75 years) and 61 young men (aged 19–35 years). Endogenous testosterone was suppressed using a monthly long-acting GnRH agonist, and participants were randomized to receive one of five weekly intramuscular doses of testosterone enanthate (25, 50, 125, 300, or 600 mg). The investigators measured changes in hemoglobin, hematocrit, serum erythropoietin (EPO), and soluble transferrin receptor (sTfR) levels.
What was found
Hemoglobin and hematocrit increased in a linear, dose-dependent fashion across both young and older men (P < 0.0001), with older men experiencing significantly greater increases than younger men. There were no statistically significant differences in percentage changes from baseline for EPO or sTfR across dose groups in either age cohort, and changes in EPO or sTfR did not significantly correlate with changes in total or free testosterone levels. Specific numerical mean changes were not reported in the abstract.
Why it matters
These findings demonstrate that older men are more susceptible to testosterone-induced erythrocytosis than younger men, and suggest that this heightened erythropoietic response operates through pathways independent of changes in circulating erythropoietin or sTfR.
Limits
The study is a secondary analysis of healthy volunteers rather than men with clinical hypogonadism, which may limit generalizability to typical clinical populations. The abstract does not provide exact numerical effect sizes or confidence intervals, and the precise non-erythropoietin mechanisms driving the erythropoietic differences were not identified.
Cited by
- supports Testosterone stimulates erythropoiesis in a dose-dependent manner.